McKesson Corporation delivered a strong third quarter for fiscal year 2026, with consolidated revenues increasing by 11% to $106.2 billion. Earnings per diluted share rose by $2.64 to $9.59, and adjusted earnings per diluted share increased by 16% to $9.34. The company also generated $1.2 billion in cash flow from operations and raised its full-year adjusted EPS guidance.

McKesson Corporation announced record high revenues of $103.2 billion for the second quarter of fiscal 2026, a 10% increase year-over-year. Net income attributable to McKesson Corporation surged by 361% to $1.11 billion, and adjusted earnings per diluted share increased by 39% to $9.86. The company also generated $2.4 billion in cash flow from operations.

In Q1-26, McKesson reported GAAP revenues of $97.8 billion and GAAP EPS of $6.25, while adjusted EPS rose 5% to $8.26. Net income attributable to McKesson declined 14% to $784 million. All segments delivered year-over-year revenue growth, and the company raised its fiscal 2026 adjusted EPS outlook.

McKesson delivered a robust Q4 FY25 performance, driven by growth in U.S. pharmaceutical and specialty product volumes, particularly in oncology. The company posted a solid rise in EPS and operating income, and announced plans to separate its Medical-Surgical Solutions segment.

McKesson Corporation announced robust third-quarter results for fiscal year 2025, with consolidated revenues increasing by 18% to $95.3 billion and adjusted earnings per diluted share rising by 4% to $8.03. The company also raised its full-year adjusted EPS guidance, reflecting strong performance across its segments and strategic growth initiatives.

McKesson Corporation announced strong second-quarter results, with a 21% increase in consolidated revenues to $93.7 billion and a 13% increase in Adjusted Earnings per Diluted Share to $7.07. The company also raised its full-year adjusted EPS guidance to $32.40 to $33.00.

McKesson Corporation reported a 6% increase in consolidated revenues, reaching $79.3 billion. Adjusted Earnings per Diluted Share increased by 8% to $7.88. The company raised its fiscal 2025 Adjusted Earnings per Diluted Share guidance range to $31.75 to $32.55.

McKesson Corporation reported an 11% increase in fourth-quarter revenues, reaching $76.4 billion. However, adjusted earnings per diluted share decreased by 14% to $6.18, driven by a higher tax rate, partially offset by a lower share count and growth in the U.S. Pharmaceutical segment.

McKesson Corporation reported a 15% increase in third quarter revenues to $80.9 billion. Earnings per diluted share decreased to $4.42, while adjusted earnings per diluted share increased by 12% to $7.74. The company raised its full year adjusted earnings per diluted share guidance to $27.25 to $27.65.

McKesson Corporation reported a 10% increase in total revenues to $77.2 billion for the second quarter of fiscal year 2024. Earnings per diluted share decreased by $1.54 to $4.92, while adjusted earnings per diluted share increased by 3% to $6.23. The company raised its full-year adjusted earnings per diluted share guidance to a range of $26.80 to $27.40.

McKesson Corporation reported strong first-quarter results for fiscal year 2024, with an 11% increase in total revenues, a significant rise in earnings per diluted share, and a raised guidance range for fiscal 2024 Adjusted Earnings per Diluted Share.

McKesson Corporation reported strong fourth-quarter and full-year results for fiscal year 2023. Fourth-quarter revenues increased by 4% to $68.9 billion, and adjusted earnings per diluted share increased by 23% to $7.19. The company also raised its long-term adjusted segment operating profit growth targets, reflecting confidence in its strategic growth prospects.

McKesson Corporation reported a 3% increase in total revenues to $70.5 billion for the third quarter of fiscal year 2023. Earnings per diluted share from continuing operations increased by $7.69 to $7.65, while Adjusted Earnings per Diluted Share increased by 12% to $6.90. The company also raised its fiscal 2023 Adjusted Earnings per Diluted Share guidance to a range of $25.75 to $26.15.

McKesson Corporation reported a 5% increase in total revenues to $70.2 billion for the second quarter of fiscal year 2023. Earnings per diluted share from continuing operations increased to $6.46, while adjusted earnings per diluted share decreased by 1% to $6.06. The company raised its full-year adjusted earnings per diluted share guidance.

McKesson Corporation reported a 7% increase in total revenues to $67.2 billion and a 5% increase in Adjusted Earnings per Diluted Share to $5.83. The company raised its fiscal 2023 Adjusted Earnings per Diluted Share guidance to $23.95 to $24.65.

McKesson reported a 12% increase in fourth-quarter revenues, reaching $66.1 billion. However, earnings per diluted share decreased, while adjusted earnings per diluted share increased by 15%. The company's full-year revenue also increased by 11%.

McKesson's Q3 2022 results showed a 10% increase in total revenues to $68.6 billion and a 34% increase in adjusted earnings per diluted share to $6.15. The company raised its fiscal 2022 adjusted earnings per diluted share guidance to $23.55 to $23.95.

McKesson Corporation reported strong second-quarter results for the period ended September 30, 2021. Total revenues increased by 9% driven by growth in the U.S. Pharmaceutical segment. Adjusted Earnings per Diluted Share increased by 28%. The company raised its fiscal 2022 Adjusted Earnings per Diluted Share guidance range to $21.95 to $22.55.

McKesson Corporation reported a strong first quarter with total revenues increasing by 13% to $62.7 billion and adjusted earnings per diluted share increasing by 101% to $5.56. The company is raising its fiscal 2022 adjusted EPS guidance based on this performance.

McKesson's fourth-quarter revenues increased by 1% to $59.1 billion, driven by market growth and higher volumes from retail national account customers in the U.S. Pharmaceutical segment. The company's adjusted EPS increased by 18% to $5.05, primarily driven by COVID-19 vaccine distribution and kitting programs.

McKesson reported a 6% increase in third-quarter revenues, reaching $62.6 billion. Adjusted earnings per diluted share rose by 21% to $4.60. The company recorded a pre-tax charge of $8.1 billion related to opioid litigation, resulting in a Loss per diluted share of $(39.03).

McKesson reported a 6% increase in total revenues, reaching $60.8 billion. Earnings per diluted share increased to $3.54, and adjusted earnings per diluted share rose by 33% to $4.80. The company also completed a joint venture of its German wholesale business with Walgreens Boots Alliance.

McKesson reported flat revenues year-over-year at $55.7 billion. However, earnings per diluted share increased by 20% to $2.72. Adjusted earnings per diluted share decreased by 16% to $2.77. The company raised its fiscal year 2021 adjusted earnings per diluted share guidance to a range of $14.70 to $15.50.

McKesson reported a 12% increase in fourth-quarter revenues to $58.5 billion and an adjusted EPS of $4.27, a 16% increase year-over-year. The results reflect continued momentum and progress in McKesson's transformation towards becoming a more focused organization. The company generated $3.9 billion of free cash flow and successfully completed the exit of its investment in Change Healthcare.